The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Open accessAbstract
There has been significant progress in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the introduction of targeted agents and immunotherapies. In this review, we discuss current and emerging first-line treatment options, including recent approvals of the tyrosine kinase inhibitor (TKI) cabozantinib and the immunotherapy combination of nivolumab (anti-programmed cell death 1 [PD-1])/ipilimumab (anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]), and initial outcomes with the combination of atezolizumab (anti-PD-ligand 1 [PD-L1])/bevacizumab (anti-vascular endothelial growth factor [VEGF]). Key clinical data are reviewed, as these novel first-line treatments offer significant improvement, particularly for patients classified as intermediate/poor risk for whom previously available therapies have demonstrated limited efficacy. Treatment recommendations based on clinical evidence and expert opinion are discussed. We also review ongoing studies investigating combinations of checkpoint inhibitors with TKIs, including cabozantinib and axitinib, and with other novel immunomodulatory agents, and the potential role of single-agent immunotherapy for select patients. With a growing treatment armamentarium, identification and validation of biomarkers will be crucial for optimizing first-line selection and treatment sequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“The combination of nivolumab/ ipilimumab has been shown to be more efficacious than either agent alone for patients with melanoma [42].”
BackgroundNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,086
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Self-citationGenomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Self-citationPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationDerosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
2004 WHO Classification of the Renal Tumors of the Adults
Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Kirkali, Z. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.035 · Cited by 893
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Gruenvald, V., & Horwich, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw328 · Cited by 509
Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 505
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6270 · Cited by 482
McDermott, D. F., Drake, C. G., Sznol, M., Choueiri, T. K., Powderly, J. D., Smith, D. C., Brahmer, J. R., Carvajal, R. D., Hammers, H. J., Puzanov, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1041 · Cited by 439
Self-citationEscudier, B., Porta, C., Bono, P., Powles, T., Eisen, T., Sternberg, C. N., Gschwend, J. E., De Giorgi, U., Parikh, O., Hawkins, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8267 · Cited by 436
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.012 · Cited by 398
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N., Wood, C. G., Matin, S. F., et al. (2016) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 395
Self-citationThe VHL/HIF axis in clear cell renal carcinoma
Shen, C., & Kaelin, W. G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.001 · Cited by 388
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 374
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Self-citationPD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1400731 · Cited by 271
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30107-4 · Cited by 260
Self-citationActive surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Rini, B. I., Dorff, T. B., Elson, P., Rodriguez, C. S., Shepard, D., Wood, L., Humbert, J., Pyle, L., Wong, Y.-N., Finke, J. H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30196-6 · Cited by 257
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233
Selby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1106 · Cited by 222
Self-citationVoss, M. H., Hakimi, A. A., Pham, C. G., Brannon, A. R., Chen, Y.-B., Cunha, L. F., Akin, O., Liu, H., Takeda, S., Scott, S. N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2345 · Cited by 214
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Motzer, R. J., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J.-L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.578 · Cited by 199
Self-citationImmunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Manola, J., Royston, P., Elson, P., McCormack, J. B., Mazumdar, M., Négrier, S., Escudier, B., Eisen, T., Dutcher, J., Atkins, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0553 · Cited by 187
Self-citationPowles, T., Albiges, L., Staehler, M., Bensalah, K., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T. B., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.11.016 · Cited by 183
Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P. F., Dieterich, L. C., Kreuger, J., & Dimberg, A. (2015) · The FASEB Journal · doi:10.1096/fj.14-250985 · Cited by 182
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Iacovelli, R., Nolè, F., Verri, E., Renne, G., Paglino, C., Santoni, M., Cossu Rocca, M., Giglione, P., Aurilio, G., Cullurà, D., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0392-7 · Cited by 178
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
Gibney, G. T., Aziz, S. A., Camp, R. L., Conrad, P., Schwartz, B. E., Chen, C. R., Kelly, W. K., & Kluger, H. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mds463 · Cited by 177
Hannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 162
McDermott, D. F., Cheng, S., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 160
Self-citationHannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaïb, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Rini, B. I., McDermott, D. F., Hammers, H. J., Bro, W., Bukowski, R. M., Faba, B., Faba, J., Figlin, R. A., Hutson, T. E., Jonasch, E. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0180-7 · Cited by 124
Self-citationOverview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors
Lenihan, D. J., & Kowey, P. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0466 · Cited by 122
Immune Consequences of Tyrosine Kinase Inhibitors that Synergize with Cancer Immunotherapy
Kwilas, A. R., Donahue, R. N., Tsang, K. Y., & Hodge, J. W. (2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.677 · Cited by 122
Complexity of tumor vasculature in clear cell renal cell carcinoma
Qian, C., Huang, D., Wondergem, B., & Teh, B. T. (2009) · Cancer · doi:10.1002/cncr.24238 · Cited by 120
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Rijnders, M., de Wit, R., Boormans, J. L., Lolkema, M. P., & van der Veldt, A. A. M. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.012 · Cited by 116
Garant, A., Guilbault, C., Ekmekjian, T., Greenwald, Z. R., Murgoi, P., & Vuong, T. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.009 · Cited by 111
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
Leite, K. R. M., Reis, S. T., Junior, J. P., Zerati, M., Gomes, D. D. O., Camara-Lopes, L. H. A., & Srougi, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0414-x · Cited by 98
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Seeber, A., Klinglmair, G., Fritz, J., Steinkohl, F., Zimmer, K., Aigner, F., Horninger, W., Gastl, G. A., Zelger, B. G., Brunner, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13560 · Cited by 78
Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Tannir, N. M., Pal, S. K., & Atkins, M. B. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0534 · Cited by 76
Self-citationAtkins, M. B., McDermott, D. F., Powles, T. B., Motzer, R. J., Rini, B. I., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4505 · Cited by 75
Self-citationLara, P. N., Bauer, T. M., Hamid, O., Smith, D. C., Gajewski, T. F., Gangadhar, T. C., Somer, B. G., Schmidt, E. V., Zhao, Y., Gowda, H. N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4515 · Cited by 67
Cella, D. F., Escudier, B. J., Tannir, N. M., Powles, T. B., Donskov, F. N., Peltola, K. J., Schmidinger, M., Heng, D. Y. C., Mainwaring, P. N., Hammers, H. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2170 · Cited by 60
Self-citationShah, D. R., Dholakia, S., & Shah, R. R. (2014) · Drug Safety · doi:10.1007/s40264-014-0139-x · Cited by 53
Rodríguez‐Vida, A., Strijbos, M. H., & Hutson, T. E. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000013 · Cited by 37
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
Bjoern, J., Lyngaa, R., Andersen, R. S., Hölmich, L. R., Hadrup, S. R., Donia, M., & Svane, I. M. (2017) · Oncotarget · doi:10.18632/oncotarget.16003 · Cited by 33
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
Lee, C., Makker, V., Rasco, D., Taylor, M. H., Dutcus, C. E., Shumaker, R. C., Schmidt, E. V., Stepan, D. E., Li, D., & Motzer, R. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx371.002 · Cited by 28
Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
Escudier, B. J., Barthélémy, P., Ravaud, A., Négrier, S., Needle, M. N., & Albiges, L. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.618 · Cited by 21
Diab, A. K., Tannir, N. M., Bernatchez, C., Haymaker, C., Bentebibel, S.-E., Curti, B. D., Wong, M. K., Gergel, I. P., Tagliaferri, M. A., Zalevsky, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e14040 · Cited by 14
Self-citationTannir, N. M., Hammers, H. J., Amin, A., Grimm, M., Rini, B. I., Mekan, S. F., McHenry, M. B., & Kollmannsberger, C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.686 · Cited by 8
Self-citation
Cited by
Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30413-9 · Cited by 775
Self-citationPowles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
Self-citationIntegrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
Borcherding, N., Vishwakarma, A., Voigt, A. P., Bellizzi, A., Kaplan, J., Nepple, K., Salem, A. K., Jenkins, R. W., Zakharia, Y., & Zhang, W. (2021) · Communications Biology · doi:10.1038/s42003-020-01625-6 · Cited by 364
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Self-citation
Metadata
- Authors
- Atkins, M. B., & Tannir, N. M.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 70
- Pages
- 127-137
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2884170377
- Cited by
- 392
- References
- 81
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.